iTeos Therapeutics SA, a Belgian biotechnology company developing novel cancer immunotherapies, announced the completion of an oversubscribed $75 million (€64 million) Series B financing.
Proceeds from this financing will support the advancement of several promising best-in-class immuno-oncology programs within iTeos’ unique pipeline into the clinic. This financing will also support the company’s expansion into its new U.S.-based offices in Cambridge, Massachusetts. Specifically, the funding will enable iTeos to move EOS100850, an adenosine A2A antagonist, into the clinic in 2018 and toward clinical proof-of-concept, and EOS884448, an anti-TIGIT antibody, into the clinic in 2019. The Company’s development pipeline also includes additional drug candidates targeting the tumor microenvironment.
iTeos Therapeutics (Gosselies, Belgium) is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies.